Strongbridge Biopharma plc: management transactions · United States · SEC (Form 4)

About Strongbridge Biopharma plc

Strongbridge Biopharma plc was a rare-disease and endocrinology-focused biopharmaceutical company listed on NASDAQ in the United States. The company was incorporated in Ireland on May 26, 2015, originally under the name Cortendo plc, and later operated with its principal executive offices in Trevose, Pennsylvania, United States. That structure gave Strongbridge a transatlantic profile: an Irish legal entity with U.S.-based commercial and operational leadership. Its business model centered on acquiring, developing, and commercializing therapies for rare disorders with significant unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1634432/000155837021002288/sbbp-20201231x10k.htm?utm_source=openai)) Strongbridge’s portfolio was built through targeted asset acquisitions rather than broad internal discovery. The company secured U.S. rights to KEVEYIS, the first and only FDA-approved treatment for certain forms of primary periodic paralysis, and later added MACRILEN, an oral diagnostic product for adult growth hormone deficiency. It also advanced RECORLEV (levoketoconazole), an adrenal steroidogenesis inhibitor developed for endogenous Cushing’s syndrome, while maintaining a preclinical program for veldoreotide extended release, a next-generation somatostatin analog being explored for acromegaly and potentially other receptor-mediated indications. This mix shows a classic specialty-pharma strategy: focus on niche endocrine assets, regulatory pathways with orphan-like characteristics, and high medical-value use cases. ([globenewswire.com](https://www.globenewswire.com/news-release/2016/12/23/901543/0/en/Strongbridge-Biopharma-plc-Announces-Acquisition-of-U-S-Rights-to-KEVEYIS-From-Taro.html?utm_source=openai)) From a competitive standpoint, Strongbridge was not trying to compete as a large-scale diversified pharma company. Instead, it aimed to build a concentrated rare-disease franchise where clinical differentiation, physician awareness, and regulatory execution matter more than manufacturing scale. Its products addressed small patient populations, which can support pricing power and commercialization resilience, but also create dependence on a limited number of assets. Geographically, the company’s core footprint was the United States, though it also held Canadian rights for some products and maintained international roots through Ireland and Sweden. ([globenewswire.com](https://www.globenewswire.com/news-release/2018/01/17/1295620/37274/en/strongbridge-biopharma-plc-announces-acquisition-of-the-u-s-and-canadian-rights-to-macrilen-macimorelin-from-aeterna-zentaris.html?utm_source=openai)) The most important recent development in Strongbridge’s history was its acquisition by Xeris Pharmaceuticals. The transaction was announced in May 2021 and completed in October 2021, after which Strongbridge ceased to trade as an independent public company. For investors, that means SBBP is primarily of historical relevance today, including for reviewing legacy SEC filings such as Form 4 insider transaction records, rather than as an active standalone equity story. ([businesswire.com](https://www.businesswire.com/news/home/20210524005257/en/Xeris-Pharmaceuticals-Inc.-to-Acquire-Strongbridge-Biopharma-plc-in-Stock-and-CVR-Transaction-Creating-an-Innovative-Leader-in-Endocrinology-and-Rare-Diseases?utm_source=openai))